A Study for the Treatment of Hormone Refractory Prostate Cancer (HRPC) in Patients Previously Treated With Chemotherapy

Phase 2

Completed

• Conditions: Prostate Cancer; Cancer of Prostate; Prostatic Cancer; Cancer of the Prostate

• Registration Number: NCT00257478
• Lead Sponsor: Astellas Pharma Inc

Brief Summary

A study for the treatment of hormone refractory prostate cancer (HRPC) in patients previously treated with chemotherapy.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2005-11-22
• Study First Submitted QC: 2005-11-22
• Study First Posted: 2005-11-23
• Study Completion: 2007-03
• Status Verified: 2012-06
• Last Update Submitted: 2012-06-06
• Last Update Posted: 2012-06-07

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: Not specified

Inclusion Criteria

• Histologically or cytologically confirmed prostate cancer.
• Prior chemotherapy regimen for prostate cancer

Exclusion Criteria

• History of other malignancy in the last 5 years
• Major surgery within the past 21 days

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP